|
ContraVir Pharmaceuticals awarded grant from NRC to advance CRV431
ContraVir Pharmaceuticals, Inc a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies announced that the company was awarded a $297,875 CAD research grant from the National Research Council in Canada.
|
|
OSE Immunotherapeutics signs a license option agreement with Servier to develop the product Effi-7
OSE Immunotherapeutics SA announced that the company has entered into a worldwide license option agreement with Servier, an independent international pharmaceutical company, for the development and commercialization of OSE ...
|
|